Covid-19 crisis: EU threatens to block exports of AstraZeneca vaccines

The European Commission is to lay out the criteria under which such exports would be evaluated on Friday

AstraZeneca
EU rules on monitoring and authorising exports of Covid-19 vaccines in the 27-nation bloc could lead to exports being blocked
John Chalmers & Philip Blenkinsop | Reuters Brussels
3 min read Last Updated : Jan 29 2021 | 1:43 AM IST
Europe's fight to secure Covid-19 vaccine supplies intensified on Thursday when the European Union warned drug companies such as AstraZeneca that it would use all legal means or even block exports unless they agreed to deliver shots as promised. The EU, whose member states are far behind Israel, the United Kingdom and the United States in rolling out vaccines, is scrambling to get supplies just as the West's biggest drugmakers slow deliveries to the bloc due to production problems. As vaccination centres in Germany, France and Spain cancelled or delayed appointments, the EU publicly rebuked Anglo-Swedish drugmaker AstraZeneca for failing to deliver and even asked if it could divert supplies from Britain.
 
European Council President Charles Michel said in a letter to four EU leaders that the EU should explore legal means to ensure supplies of vaccines it contracted to buy if negotiations with firms over delayed deliveries are unsuccessful.
 
"If no satisfactory solution can be found, I believe we should explore all options and make use of all legal means and enforcement measures at our disposal under the Treaties," Michel said in the Jan. 27 letter.
 
EU rules on monitoring and authorising exports of Covid-19 vaccines in the 27-nation bloc could lead to exports being blocked if they violated existing contracts between the vaccine maker and the EU, an EU official said. The European Commission is to lay out the criteria under which such exports would be evaluated on Friday.
 
Vaccine crunch
 
Under fire from the EU, AstraZeneca CEO Pascal Soriot said the EU was late to strike a supply contract so the company did not have enough time to iron out production problems at a vaccine factory run by a partner in Belgium. Britain, which has repeatedly touted its lead in the vaccine rollout race since leaving the EU's orbit on January 1, said its deliveries must be honoured. "I think we need to make sure that the vaccine supply that has been bought and paid for, procured for those in the UK, is delivered," Minister for the Cabinet Office Michael Gove said.
 
Asked if the British government would prevent AstraZeneca diverting essential vaccine supplies from Britain to the EU, Gove said the crucial thing was that Britain received its orders as planned and on time.
 
The swiftest mass vaccination drive in history is stoking tensions across the world as big powers buy up doses in bulk and poorer nations try to navigate a financial and diplomatic minefield to collect whatever supplies are left. In the northern French region of Hauts-de-France, France's second-most-densely-populated region, several vaccination centres were no longer taking appointments for a first jab. In several other French regions, some online appointment platforms closed booking options.
 
Spain's Madrid region has ceased first vaccinations for at least this week and next and was using the few doses it has to administer second shots to those who have had the first one, said deputy regional government chief Ignacio Aguado.Germany’s most populous state, North Rhine-Westphalia, last week postponed opening its vaccination centres, while the state of Brande-nburg has also pushed back vaccination originally scheduled for the end of January.
 

Germany recommends Astra shot only for people under 65
 
Germany cast doubt on AstraZeneca’s shot for the elderly in a move that could perpetuate the EU’s  vaccine supply shortages. The country’s immunization commission recommended that the drugmaker’s inoculation be authorized only for people between the ages of 18 and 64, according to a draft assessment.



One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :European UnionAstraZenecaCoronavirus Vaccine

Next Story